Immunological Studies of Coagulation Factor XIII
AUTOR(ES)
Israels, E. D.
RESUMO
Human fibrin-stabilizing factor (Factor XIII) has been studied immunologically by the preparation of specific anti-Factor XIII antiserum in rabbits. On immunodiffusion it was found that normal plasma produced two precipitin lines. One of the precipitin lines was identical with that present in soluble platelet extract (the α-component), the other with that present in normal serum (β-component). Plasma and serum of patients with congenital Factor XIII deficiency contained only the β-component. By adsorption it was possible to prepare a second antiserum with solely anti-α-activity that did not react with the serum or plasma of XIII-deficient patients. Both antisera neutralized the clot-stabilizing activity of normal plasma. The action of thrombin on fibrinogen-free plasma or platelet extract abolished the immunoprecipitin α-line but did not reduce the capacity to neutralize antibody as measured by clot stabilization.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=302497Documentos Relacionados
- Three-dimensional structure of a transglutaminase: human blood coagulation factor XIII.
- Cleavage of blood coagulation factor XIII and fibrinogen by thrombin during in vitro clotting.
- Characterization of the gene for the a subunit of human factor XIII (plasma transglutaminase), a blood coagulation factor.
- Tetranucleotide repeat polymorphism at the human coagulation factor XIII A subunit gene (F13A1)
- Localization of the gene for coagulation factor XIII a-chain to chromosome 6 and identification of sites of synthesis.